NCT07119996View on ClinicalTrials.gov

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions
Bladder (Urothelial, Transitional Cell) Cancer
Interventions
DRUG

Tislelizumab, Cisplatin, Gemcitabine and Vitamin B3

"1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W.~4. Vitamin B3 tablet(also known as nicotinic acid tablet) supplementation daily(300mg QD or 500mg QD) after antibiotic treatment."

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER